Charles Monier, MD
Gastroenterology · Thibodaux, LANPI 1043288160
Payments from drug & device makers
What this record shows
This record is dominated by other: $443,504 of the $447,981 with a category attached, or 99.0%. Zimmer Biomet accounts for 99.0% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $444,047 and has fallen 99.9% since, to $554 in 2025. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $1413.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$444K
- AbbVie$1K
- Redhill Biopharma Inc.$470
- Takeda Pharmaceuticals U.S.A., Inc.$404
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$403
- Bristol Myers Squibb$399
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,4451%
- Education$320%
- Other$443,50499%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 1 | $443,504 |
| AbbVie(2 entities) | 98 | $1,129 |
| Redhill Biopharma Inc. | 38 | $470 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $404 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $403 |
| Bristol Myers Squibb | 26 | $399 |
| Johnson & Johnson | 17 | $241 |
| Pfizer | 13 | $218 |
| Ironwood Pharmaceuticals, Inc | 11 | $191 |
| Romark Laboratories, LC | 8 | $141 |
| Intercept Pharmaceuticals, Inc. | 8 | $126 |
| Sanofi | 5 | $118 |
| Ferring Pharmaceuticals Inc. | 5 | $74 |
| QOL Medical, LLC | 4 | $73 |
| Braintree Laboratories, Inc. | 4 | $65 |
| Phathom Pharmaceuticals, Inc. | 5 | $60 |
| Madrigal Pharmaceuticals | 2 | $48 |
| Concordia Pharmaceuticals Inc. | 2 | $45 |
| Merck | 2 | $43 |
| Abbott | 1 | $28 |
| Boehringer Ingelheim | 2 | $27 |
| Celltrion USA Inc. | 1 | $25 |
| Axonics, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Sandoz | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Gilead | 1 | $15 |
| Organon | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$447,981 in reported general payments places this provider in the 95th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 47 | $101,731 |
| InflectraInfliximab-Dyyb | 13 | $96,865 |
| Humira(Cf) PenAdalimumab | 13 | $96,699 |
| RinvoqUpadacitinib | 13 | $82,264 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 351 | $56,454 |
| ZenpepLipase/Protease/Amylase | 44 | $51,980 |
| Mesalamine | 90 | $27,621 |
| LinzessLinaclotide | 18 | $24,443 |
| ViberziEluxadoline | 11 | $18,167 |
| Sucralfate | 210 | $14,505 |
| Pantoprazole Sodium | 857 | $9,543 |
| Mesalamine ErMesalamine | 54 | $8,620 |
| Dexlansoprazole DrDexlansoprazole | 31 | $8,614 |
| Colestipol Hcl | 148 | $7,373 |
| Omeprazole | 275 | $3,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Rinvoq, Linzess, Viberzi | $1,129 | $226,60689 claims |
| PfizerInflectra | $218 | $96,86513 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $74 | $56,454351 claims |
| SandozLansoprazole | $18 | $1,79726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Thibodaux
- Justin ToupsThibodaux$24K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
- Sarah GloverNew Orleans$274K
- Nisha LoganantharajNew Orleans$173K
- Shamita ShahNew Orleans$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.